{"transactions":[{"id":678559,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-21T20:23:22.000Z","date":"2026-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":36645,"price":8.08,"value":296091.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026."}],"balance_after":2898933,"source":{"system":"sec-edgar","filing":"0001867096-26-000073","document":"wk-form4_1787343799.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709626000073/wk-form4_1787343799.xml","form_type":"4"}},{"id":924549,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-02T23:13:18.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":639639,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date."}],"balance_after":639639,"derivative":{"exercise_price":7.36,"expiration_date":"2036-01-30","underlying":"Common Stock","underlying_shares":639639},"source":{"system":"sec-edgar","filing":"0001553595-26-000004","document":"wk-form4_1770073996.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000004/wk-form4_1770073996.xml","form_type":"4"}},{"id":924548,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-02T23:13:18.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":110750,"price":7.36,"value":815120.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026."}],"balance_after":2935578,"source":{"system":"sec-edgar","filing":"0001553595-26-000004","document":"wk-form4_1770073996.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000004/wk-form4_1770073996.xml","form_type":"4"}},{"id":924547,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-02T23:13:18.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":111621,"price":7.36,"value":821530.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026."}],"balance_after":3046328,"source":{"system":"sec-edgar","filing":"0001553595-26-000004","document":"wk-form4_1770073996.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000004/wk-form4_1770073996.xml","form_type":"4"}},{"id":924546,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-02T23:13:18.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":118134,"price":7.36,"value":869466.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026."}],"balance_after":3157949,"source":{"system":"sec-edgar","filing":"0001553595-26-000004","document":"wk-form4_1770073996.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000004/wk-form4_1770073996.xml","form_type":"4"}},{"id":924545,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-02T23:13:18.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":478436,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the \"Plan\"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date."}],"balance_after":3276083,"source":{"system":"sec-edgar","filing":"0001553595-26-000004","document":"wk-form4_1770073996.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000004/wk-form4_1770073996.xml","form_type":"4"}},{"id":945774,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T23:14:28.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":false,"shares":2900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person received the stock options on August 26, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 25% of the options vested on the first\nanniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such\nvesting date."}],"balance_after":97100,"derivative":{"exercise_price":3.94,"expiration_date":"2030-08-26","underlying":"Common Stock","underlying_shares":2900},"source":{"system":"sec-edgar","filing":"0001553595-26-000002","document":"wk-form4_1767741265.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000002/wk-form4_1767741265.xml","form_type":"4"}},{"id":945773,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T23:14:28.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":false,"shares":25136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person received the stock options on June 12, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first\nanniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such\nvesting date."}],"balance_after":0,"derivative":{"exercise_price":1.55,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":25136},"source":{"system":"sec-edgar","filing":"0001553595-26-000002","document":"wk-form4_1767741265.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000002/wk-form4_1767741265.xml","form_type":"4"}},{"id":945772,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T23:14:28.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":false,"shares":64265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person received the stock options on February 4, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first\nanniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such\nvesting date."}],"balance_after":0,"derivative":{"exercise_price":1.55,"expiration_date":"2027-02-04","underlying":"Common Stock","underlying_shares":64265},"source":{"system":"sec-edgar","filing":"0001553595-26-000002","document":"wk-form4_1767741265.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000002/wk-form4_1767741265.xml","form_type":"4"}},{"id":945771,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-01-06T23:14:28.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":true,"shares":2900,"price":3.94,"value":11426.0,"ownership":{"direct":true},"balance_after":2797647,"source":{"system":"sec-edgar","filing":"0001553595-26-000002","document":"wk-form4_1767741265.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000002/wk-form4_1767741265.xml","form_type":"4"}},{"id":945770,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-01-06T23:14:28.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":true,"shares":25136,"price":1.55,"value":38960.8,"ownership":{"direct":true},"balance_after":2794747,"source":{"system":"sec-edgar","filing":"0001553595-26-000002","document":"wk-form4_1767741265.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000002/wk-form4_1767741265.xml","form_type":"4"}},{"id":945769,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-01-06T23:14:28.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":true,"shares":64265,"price":1.55,"value":99610.75,"ownership":{"direct":true},"balance_after":2769611,"source":{"system":"sec-edgar","filing":"0001553595-26-000002","document":"wk-form4_1767741265.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000002/wk-form4_1767741265.xml","form_type":"4"}},{"id":945768,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-01-06T23:14:28.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":24907,"price":7.0766,"value":176256.8762,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.040 to $7.350, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2705346,"source":{"system":"sec-edgar","filing":"0001553595-26-000002","document":"wk-form4_1767741265.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359526000002/wk-form4_1767741265.xml","form_type":"4"}},{"id":997529,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-17T22:58:52.000Z","date":"2025-11-14","kind":"exercise","planned":false,"acquired":false,"shares":87100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date."}],"balance_after":64265,"derivative":{"exercise_price":1.55,"expiration_date":"2027-02-03","underlying":"Common Stock","underlying_shares":87100},"source":{"system":"sec-edgar","filing":"0001553595-25-000004","document":"wk-form4_1763420330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359525000004/wk-form4_1763420330.xml","form_type":"4"}},{"id":997528,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-17T22:58:52.000Z","date":"2025-11-13","kind":"exercise","planned":false,"acquired":false,"shares":8970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date."}],"balance_after":151365,"derivative":{"exercise_price":1.55,"expiration_date":"2027-02-03","underlying":"Common Stock","underlying_shares":8970},"source":{"system":"sec-edgar","filing":"0001553595-25-000004","document":"wk-form4_1763420330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359525000004/wk-form4_1763420330.xml","form_type":"4"}},{"id":997527,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-17T22:58:52.000Z","date":"2025-11-14","kind":"exercise","planned":false,"acquired":true,"shares":87100,"price":1.55,"value":135005.0,"ownership":{"direct":true},"balance_after":2730253,"source":{"system":"sec-edgar","filing":"0001553595-25-000004","document":"wk-form4_1763420330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359525000004/wk-form4_1763420330.xml","form_type":"4"}},{"id":997526,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-17T22:58:52.000Z","date":"2025-11-13","kind":"sale","planned":false,"acquired":false,"shares":23242,"price":7.4607,"value":173401.5894,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.260 to $7.740, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2643153,"source":{"system":"sec-edgar","filing":"0001553595-25-000004","document":"wk-form4_1763420330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359525000004/wk-form4_1763420330.xml","form_type":"4"}},{"id":997525,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-17T22:58:52.000Z","date":"2025-11-13","kind":"exercise","planned":false,"acquired":true,"shares":8970,"price":1.55,"value":13903.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2666395,"source":{"system":"sec-edgar","filing":"0001553595-25-000004","document":"wk-form4_1763420330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000155359525000004/wk-form4_1763420330.xml","form_type":"4"}},{"id":1076061,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-08-04T20:24:53.000Z","date":"2025-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":36918,"price":5.38,"value":198618.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include 7,225 shares that were purchased on June 30, 2025, due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan"}],"balance_after":2657425,"source":{"system":"sec-edgar","filing":"0001867096-25-000124","document":"wk-form4_1754339089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709625000124/wk-form4_1754339089.xml","form_type":"4"}},{"id":1287045,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Appreciation Right","published_at":"2025-02-04T00:40:13.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the January 31, 2025 grant date, subject to continued service with the company through the vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Upon exercise, the stock appreciation right will be settled in cash."}],"balance_after":600000,"derivative":{"exercise_price":3.56,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001867096-25-000026","document":"wk-form4_1738629606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709625000026/wk-form4_1738629606.xml","form_type":"4"}},{"id":1287044,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-04T00:40:13.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."}],"balance_after":2687118,"source":{"system":"sec-edgar","filing":"0001867096-25-000026","document":"wk-form4_1738629606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709625000026/wk-form4_1738629606.xml","form_type":"4"}},{"id":1287043,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-04T00:40:13.000Z","date":"2025-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":110750,"price":3.56,"value":394270.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025."}],"balance_after":1887118,"source":{"system":"sec-edgar","filing":"0001867096-25-000026","document":"wk-form4_1738629606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709625000026/wk-form4_1738629606.xml","form_type":"4"}},{"id":1287042,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-04T00:40:13.000Z","date":"2025-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":110750,"price":3.56,"value":394270.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025."}],"balance_after":1997868,"source":{"system":"sec-edgar","filing":"0001867096-25-000026","document":"wk-form4_1738629606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709625000026/wk-form4_1738629606.xml","form_type":"4"}},{"id":1307584,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-07T21:43:31.000Z","date":"2025-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":39443,"price":3.61,"value":142389.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of Restricted Stock Units vested as of January 3, 2025."}],"balance_after":2108618,"source":{"system":"sec-edgar","filing":"0001867096-25-000015","document":"wk-form4_1736286205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709625000015/wk-form4_1736286205.xml","form_type":"4"}},{"id":1442502,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Appreciation Right","published_at":"2024-08-02T21:22:51.000Z","date":"2024-08-01","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The award will vest in full on the two-year anniversary of the grant date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"Upon exercise, the Stock Appreciation Right will be settled in cash."}],"balance_after":300000,"derivative":{"exercise_price":2.43,"expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001867096-24-000145","document":"wk-form4_1722633763.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000145/wk-form4_1722633763.xml","form_type":"4"}},{"id":1442501,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-02T21:22:51.000Z","date":"2024-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":110750,"price":2.46,"value":272445.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F11","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024."}],"balance_after":2148061,"source":{"system":"sec-edgar","filing":"0001867096-24-000145","document":"wk-form4_1722633763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000145/wk-form4_1722633763.xml","form_type":"4"}},{"id":1442500,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-02T21:22:51.000Z","date":"2024-01-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":22150,"price":2.66,"value":58919.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F10","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024."}],"balance_after":2258811,"source":{"system":"sec-edgar","filing":"0001867096-24-000145","document":"wk-form4_1722633763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000145/wk-form4_1722633763.xml","form_type":"4"}},{"id":1442499,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-02T21:22:51.000Z","date":"2024-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":40834,"price":2.24,"value":91468.16,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F9","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024."}],"balance_after":2280961,"source":{"system":"sec-edgar","filing":"0001867096-24-000145","document":"wk-form4_1722633763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000145/wk-form4_1722633763.xml","form_type":"4"}},{"id":1442498,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-02T21:22:51.000Z","date":"2023-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":9880,"price":1.24,"value":12251.2,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F8","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023."}],"balance_after":2321795,"source":{"system":"sec-edgar","filing":"0001867096-24-000145","document":"wk-form4_1722633763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000145/wk-form4_1722633763.xml","form_type":"4"}},{"id":1442497,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-02T21:22:51.000Z","date":"2023-01-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":23414,"price":1.26,"value":29501.64,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F7","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023."}],"balance_after":2331675,"source":{"system":"sec-edgar","filing":"0001867096-24-000145","document":"wk-form4_1722633763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000145/wk-form4_1722633763.xml","form_type":"4"}},{"id":1442496,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-02T21:22:51.000Z","date":"2023-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":41334,"price":1.12,"value":46294.08,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023."}],"balance_after":2355089,"source":{"system":"sec-edgar","filing":"0001867096-24-000145","document":"wk-form4_1722633763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000145/wk-form4_1722633763.xml","form_type":"4"}},{"id":1442495,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-02T21:22:51.000Z","date":"2022-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":7497,"price":2.11,"value":15818.67,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022."}],"balance_after":2396423,"source":{"system":"sec-edgar","filing":"0001867096-24-000145","document":"wk-form4_1722633763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000145/wk-form4_1722633763.xml","form_type":"4"}},{"id":1442494,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-02T21:22:51.000Z","date":"2022-01-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":15692,"price":2.11,"value":33110.12,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"This transaction is being reported late due to administrative oversight."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022."}],"balance_after":2403920,"source":{"system":"sec-edgar","filing":"0001867096-24-000145","document":"wk-form4_1722633763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000145/wk-form4_1722633763.xml","form_type":"4"}},{"id":1442493,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-02T21:22:51.000Z","date":"2024-08-01","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include 11,037 shares that were purchased on June 30, 2024, due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":2419612,"source":{"system":"sec-edgar","filing":"0001867096-24-000145","document":"wk-form4_1722633763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000145/wk-form4_1722633763.xml","form_type":"4"}},{"id":1664884,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-31T22:05:13.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."}],"balance_after":2158575,"source":{"system":"sec-edgar","filing":"0001867096-24-000017","document":"wk-form4_1706738697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709624000017/wk-form4_1706738697.xml","form_type":"4"}},{"id":1736107,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-17T22:58:32.000Z","date":"2023-11-17","kind":"purchase","planned":false,"acquired":true,"shares":30769,"price":1.638,"value":50399.622,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6250 to $1.6400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":1408575,"source":{"system":"sec-edgar","filing":"0001867096-23-000145","document":"wk-form4_1700261903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709623000145/wk-form4_1700261903.xml","form_type":"4"}},{"id":2038278,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-02-01T21:13:59.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include 8,896 shares that were purchased on June 30, 2022 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":1377806,"source":{"system":"sec-edgar","filing":"0001867096-23-000024","document":"wf-form4_167528602235679.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709623000024/wf-form4_167528602235679.xml","form_type":"4"}},{"id":2442864,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-01-05T23:16:22.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include 5,081 shares that were purchased on June 30, 2021 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan."}],"balance_after":618910,"source":{"system":"sec-edgar","filing":"0001867096-22-000008","document":"wf-form4_164142456918577.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709622000008/wf-form4_164142456918577.xml","form_type":"4"}},{"id":2514377,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-11-12T22:12:51.000Z","date":"2021-11-12","kind":"purchase","acquired":true,"shares":60000,"price":2.1,"value":126000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.09 to $2.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":363829,"source":{"system":"sec-edgar","filing":"0001867096-21-000077","document":"wf-form4_163675512137122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709621000077/wf-form4_163675512137122.xml","form_type":"4"}},{"id":2514376,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-11-12T22:12:51.000Z","date":"2021-11-11","kind":"purchase","acquired":true,"shares":40000,"price":2.0875,"value":83500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.08 to $2.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":303829,"source":{"system":"sec-edgar","filing":"0001867096-21-000077","document":"wf-form4_163675512137122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000186709621000077/wf-form4_163675512137122.xml","form_type":"4"}},{"id":2548039,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:47:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":100000,"derivative":{"exercise_price":3.94,"expiration_date":"2030-08-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-21-039333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000089924321039333/doc4.xml","form_type":"4"}},{"id":2548038,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:47:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":80000,"derivative":{"exercise_price":13.88,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-21-039333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000089924321039333/doc4.xml","form_type":"4"}},{"id":2548037,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:47:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":34977,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options are early exercisable."}],"balance_after":34977,"derivative":{"exercise_price":12.5,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":34977},"source":{"system":"sec-edgar","filing":"0000899243-21-039333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000089924321039333/doc4.xml","form_type":"4"}},{"id":2548036,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:47:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":28072,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options are early exercisable."}],"balance_after":28072,"derivative":{"exercise_price":5.93,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":28072},"source":{"system":"sec-edgar","filing":"0000899243-21-039333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000089924321039333/doc4.xml","form_type":"4"}},{"id":2548035,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:47:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":25136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options are fully vested as of the date hereof."}],"balance_after":25136,"derivative":{"exercise_price":1.55,"expiration_date":"2027-06-11","underlying":"Common Stock","underlying_shares":25136},"source":{"system":"sec-edgar","filing":"0000899243-21-039333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000089924321039333/doc4.xml","form_type":"4"}},{"id":2548034,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T23:47:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":160335,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Merger Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options are fully vested as of the date hereof."}],"balance_after":160335,"derivative":{"exercise_price":1.55,"expiration_date":"2027-02-03","underlying":"Common Stock","underlying_shares":160335},"source":{"system":"sec-edgar","filing":"0000899243-21-039333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000089924321039333/doc4.xml","form_type":"4"}},{"id":2548033,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T23:47:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":193333,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the \"HoldCo RSU\"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the \"Xeris RSU\") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the \"HoldCo RSU\"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the \"Xeris RSU\") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the \"HoldCo RSU\"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the \"Xeris RSU\") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU."}],"balance_after":263829,"source":{"system":"sec-edgar","filing":"0000899243-21-039333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000089924321039333/doc4.xml","form_type":"4"}},{"id":2548032,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T23:47:44.000Z","date":"2021-10-05","kind":"grant","acquired":true,"shares":70496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among Xeris Pharmaceuticals, Inc. (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), the Issuer (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Merger Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax."}],"balance_after":70496,"source":{"system":"sec-edgar","filing":"0000899243-21-039333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553595/000089924321039333/doc4.xml","form_type":"4"}},{"id":2548316,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:32:49.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":0,"derivative":{"exercise_price":3.94,"expiration_date":"2030-08-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-21-039242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039242/doc4.xml","form_type":"4"}},{"id":2548315,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:32:49.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":0,"derivative":{"exercise_price":13.88,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-21-039242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039242/doc4.xml","form_type":"4"}},{"id":2548314,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:32:49.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":34977,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options are early exercisable."}],"balance_after":0,"derivative":{"exercise_price":12.5,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":34977},"source":{"system":"sec-edgar","filing":"0000899243-21-039242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039242/doc4.xml","form_type":"4"}},{"id":2548313,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:32:49.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":28072,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options are early exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.93,"expiration_date":"2028-01-31","underlying":"Common Stock","underlying_shares":28072},"source":{"system":"sec-edgar","filing":"0000899243-21-039242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039242/doc4.xml","form_type":"4"}},{"id":2548312,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:32:49.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":25136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":1.55,"expiration_date":"2027-06-11","underlying":"Common Stock","underlying_shares":25136},"source":{"system":"sec-edgar","filing":"0000899243-21-039242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039242/doc4.xml","form_type":"4"}},{"id":2548311,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-05T17:32:49.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":160335,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase shares of Xeris common stock (the \"Xeris Option\") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the \"HoldCo Option\"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":1.55,"expiration_date":"2027-02-03","underlying":"Common Stock","underlying_shares":160335},"source":{"system":"sec-edgar","filing":"0000899243-21-039242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039242/doc4.xml","form_type":"4"}},{"id":2548310,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T17:32:49.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":193333,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the \"Xeris RSU\"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the \"HoldCo RSU\") on the same terms and conditions  (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the \"Xeris RSU\"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the \"HoldCo RSU\") on the same terms and conditions  (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted stock units each representing a contingent right to receive one share of Xeris common stock (the \"Xeris RSU\"). At the Effective Time, each Xeris RSU that outstanding immediately prior to the Effective Time was automatically converted into a restricted stock unit representing a contingent right to acquire one share of HoldCo common stock (the \"HoldCo RSU\") on the same terms and conditions  (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Excludes vested Xeris RSUs as of the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-039242","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039242/doc4.xml","form_type":"4"}},{"id":2548309,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-05T17:32:49.000Z","date":"2021-10-05","kind":"disposition_to_issuer","acquired":false,"shares":70496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 (\"Transaction Agreement\") by and among the Issuer (\"Xeris\"), Strongbridge Biopharma plc (\"Strongbridge\"), Xeris Biopharma Holdings, Inc. (\"HoldCo\") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo (\"MergerSub\"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the \"Acquisition\"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the \"Merger\", and together with the Acquisition, the \"Transaction\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the effective time of the Merger (the \"Effective Time\"), all existing shares of Xeris common stock (the \"Xeris common stock\") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of Xeris common stock received upon vesting of Xeris RSUs (as defined below), net of shares of Xeris common stock withheld for tax."}],"balance_after":193333,"source":{"system":"sec-edgar","filing":"0000899243-21-039242","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924321039242/doc4.xml","form_type":"4"}},{"id":2888345,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-01T16:20:53.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 29, 2022."}],"balance_after":271224,"source":{"system":"sec-edgar","filing":"0001346302-21-000014","document":"wf-form4_161221443653827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000134630221000014/wf-form4_161221443653827.xml","form_type":"4"}},{"id":3050842,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-20T18:01:38.000Z","date":"2020-08-18","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months, in all cases subject to Mr. Shannon's continuous service to the company through each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":4.29,"expiration_date":"2030-08-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-20-023069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320023069/doc4.xml","form_type":"4"}},{"id":3082462,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-15T16:53:31.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":3731,"price":2.26,"value":8432.06,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from January 1, 2020 through June 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2020."}],"balance_after":121224,"source":{"system":"sec-edgar","filing":"0000899243-20-019179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320019179/doc4.xml","form_type":"4"}},{"id":3148584,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-05-14T16:30:50.000Z","date":"2020-05-13","kind":"purchase","acquired":true,"shares":22000,"price":3.5452,"value":77994.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.44 to $3.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":117493,"source":{"system":"sec-edgar","filing":"0000899243-20-013088","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320013088/doc4.xml","form_type":"4"}},{"id":3154101,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-05-11T18:17:24.000Z","date":"2020-05-08","kind":"purchase","acquired":true,"shares":7886,"price":3.198,"value":25219.428,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.18 to $3.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":95493,"source":{"system":"sec-edgar","filing":"0000899243-20-012625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320012625/doc4.xml","form_type":"4"}},{"id":3237641,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-03-02T16:53:26.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 31, 2021."}],"balance_after":87607,"source":{"system":"sec-edgar","filing":"0000899243-20-006514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320006514/doc4.xml","form_type":"4"}},{"id":3266273,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-02-18T17:02:56.000Z","date":"2020-02-14","kind":"purchase","acquired":true,"shares":12048,"price":4.15,"value":49999.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares purchased in an underwritten public offering of the Issuer at the public offering price of $4.15 per share."}],"balance_after":22607,"source":{"system":"sec-edgar","filing":"0000899243-20-004914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320004914/doc4.xml","form_type":"4"}},{"id":3317722,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-01-06T18:09:45.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":438,"price":5.99,"value":2623.62,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from July 1, 2019 through December 31, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on December 31, 2019."}],"balance_after":10559,"source":{"system":"sec-edgar","filing":"0000899243-20-000614","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924320000614/doc4.xml","form_type":"4"}},{"id":3467530,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2019-07-03T16:56:10.000Z","date":"2019-07-01","kind":"grant","acquired":true,"shares":1138,"price":9.72,"value":11061.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from January 1, 2019 through June 30, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 28, 2019."}],"balance_after":10121,"source":{"system":"sec-edgar","filing":"0000899243-19-019198","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924319019198/doc4.xml","form_type":"4"}},{"id":3679406,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-01T16:38:48.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months."}],"balance_after":80000,"derivative":{"exercise_price":13.88,"expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-19-002323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924319002323/doc4.xml","form_type":"4"}},{"id":3882086,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series C Preferred Stock","published_at":"2018-06-27T20:35:29.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8983},"source":{"system":"sec-edgar","filing":"0000899243-18-018502","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924318018502/doc4.xml","form_type":"4"}},{"id":3882085,"issuer":{"id":134906,"kind":"organization","name":"XERIS PHARMACEUTICALS INC","symbol":"XERS"},"owners":[{"id":20765,"kind":"person","name":"Shannon John Patrick Jr","position":1,"cik":"0001553595","reported_name":"Shannon John Patrick Jr","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-06-27T20:35:29.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":8983,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date."}],"balance_after":8983,"source":{"system":"sec-edgar","filing":"0000899243-18-018502","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346302/000089924318018502/doc4.xml","form_type":"4"}}]}